發(fā)布時間：2018-04-04 15:19

  本文選題：血管成形術(shù)　切入點(diǎn)：經(jīng)腔　出處：《中國循環(huán)雜志》2017年10期

【摘要】：目的:系統(tǒng)評價中國急性冠狀動脈綜合征(ACS)患者行經(jīng)皮冠狀動脈介入治療(PCI)后應(yīng)用替格瑞洛與氯吡格雷治療的療效和安全性。方法:系統(tǒng)檢索中國知網(wǎng)、萬方、維普、CBM、Pub Med和Web of Science數(shù)據(jù)庫,搜集有關(guān)中國ACS患者行PCI術(shù)后應(yīng)用替格瑞洛與氯吡格雷治療的療效和安全性比較的隨機(jī)對照試驗(RCT),采用R軟件進(jìn)行Meta分析。結(jié)果:納入31個RCT共4 342例患者。Meta分析結(jié)果顯示:與氯吡格雷組相比,替格瑞洛組在隨訪期間主要心血管不良事件(MACE)[RR=0.37;95%CI(0.31~0.45);P0.05]、心肌梗死[RR=0.37;95%CI(0.23~0.57);P0.05]、支架內(nèi)血栓形成[RR=0.28;95%CI(0.16~0.49);P0.05]和腦卒中的發(fā)生率[RR=0.44;95%CI(0.23~0.81);P0.05]均顯著降低,但出血[RR=1.47;95%C(I1.19~1.81);P0.05]和呼吸困難發(fā)生率[RR=2.05;95%CI(1.47~2.84);P0.05]較氯吡格雷組高。結(jié)論:中國ACS患者行PCI術(shù)后,應(yīng)用替格瑞洛可降低主要心血管不良事件、心肌梗死、支架內(nèi)血栓形成和卒中的發(fā)生率,但須警惕出血及呼吸困難事件的發(fā)生。
[Abstract]:Objective: to evaluate the efficacy and safety of tigrilol and clopidogrel after percutaneous coronary intervention (PCI) in patients with acute coronary syndrome (ACS) in China.Methods: the databases of CBM Pub Med and Web of Science were searched systematically.To investigate the efficacy and safety of tigrilol and clopidogrel in the treatment of ACS patients in China, Meta analysis was performed with R software.Results: a meta-analysis of 4342 patients with 31 RCT patients showed that: compared with clopidogrel group,鏇挎牸鐟炴礇緇勫湪闅忚�挎湡闂翠富瑕佸績琛�綆′笉鑹�浜嬩�，

本文編號：1710525